Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Austar LifesciencesAULSF 49 PB Ratio is 0.09 as of Jul. 16, 2026, which is 93% below its 10-year median of 1.34. GuruFocus rates AULSF with a GF Score™ of 49/100 and a GF Value™ of $0.08 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Austar Lifesciences ranks better than 95.43% on this metric.
Austar Lifesciences Ltd stock PB Ratio (=0.39) is close to 1-year low of 0.38.
The historical rank and industry rank for Austar Lifesciences's PB Ratio or its related term are showing as below:
AULSF'
s PB Ratio Range Over the Past 10 Years
Min: 0.32 Med: 1.34 Max: 24.75
Current: 0.39
During the past 13 years, Austar Lifesciences's highest PB Ratio was 24.75. The lowest was 0.32. And the median was 1.34.
AULSF's PB Ratio is ranked better than 95.43% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.05
vs AULSF: 0.39
During the past 12 months, Austar Lifesciences's average Book Value Per Share Growth Rate was 7.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -3.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 4.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 5.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Austar Lifesciences was 55.10% per year. The lowest was -6.20% per year. And the median was -0.25% per year.
Back to Basics: PB Ratio
Austar Lifesciences (OTCPK:AULSF) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Austar Lifesciences PB Ratio Related Terms
Austar Lifesciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Austar Lifesciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Austar Lifesciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austar Lifesciences PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Austar Lifesciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Austar Lifesciences (AULSF) has a PB Ratio of 0.09 as of Jul. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Austar Lifesciences and its competitors. This is 93% below median its historical median of 1.34. Over the past decade, Austar Lifesciences' PB Ratio has ranged from 0.32 to 24.75. According to the industry distribution chart, Austar Lifesciences ranks #36 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 4.6%.
Is Austar Lifesciences' PB Ratio too high?
Austar Lifesciences' current PB Ratio of 0.09 is 93% below median its 10-year median of 1.34. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 24.75. The Medical Devices & Instruments industry median PB Ratio is 2.05. Austar Lifesciences' value of 0.09 is 95.6% below this industry median. Based on the distribution chart, Austar Lifesciences ranks #36 out of 787 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Austar Lifesciences has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Austar Lifesciences ranks #36 out of 787 companies for PB Ratio. This places Austar Lifesciences in the top 5% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.05. Austar Lifesciences' value of 0.09 is 95.6% below this benchmark. Historically, Austar Lifesciences' own PB Ratio has ranged from 0.32 to 24.75 over the past decade. While the company's 10-year median is 1.34 vs. the industry median of 2.05, Austar Lifesciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.05, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Austar Lifesciences's current PB Ratio of 0.09 is 95.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Austar Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Austar Lifesciences's current PB Ratio is 0.09, which is 93% below median its own 10-year median of 1.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Austar Lifesciences (AULSF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.08, compared to a current price of $0.02 — trading 75% below its estimated fair value. The current PB Ratio is 0.09, which is 93% below median its 10-year median of 1.34 and 95.6% below the Medical Devices & Instruments industry median of 2.05. Austar Lifesciences' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current PB Ratio is 0.09 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austar Lifesciences (AULSF) Overvalued in 2026?
Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued.
The current stock price of $0.02 is trading 75% below its estimated GF Value™ of $0.08.
GuruFocus considers Austar Lifesciences to be Possible Value Trap.
Key valuation signals for AULSF:
PB Ratio: 0.09 (93% below median its 10-year median of 1.34)
GF Value™: $0.08 vs. price of $0.02 (75% below fair value)
Industry Position: 95.6% below the Medical Devices & Instruments median (#36 of 787)
No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
49GF Score
Get the complete analysis for AULSF
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AULSF has been successfully added to your 
